Andrew J. Armstrong, MD, ScM, FACP, presented “ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life-Prolonging Therapy in mHSPC Patients” for the Grand Rounds in Urology audience in December 2019.
How to cite: Armstrong, Andrew J. “ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life-Prolonging Therapy in mHSPC Patients” December, 2019. Accessed Jan 2026. https://grandroundsinurology.com/enzamet-and-arches-trials-provides-evidence-of-enzalutamide-as-life-prolonging-therapy-in-mhspc-patients/
ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life-Prolonging Therapy in mHSPC Patients – Summary:
Andrew J. Armstrong, MD, ScM, FACP, Professor and Director of Research at Duke Cancer Institute Center for Prostate and Urologic Cancers and lead author of the ARCHES study, gives an overview of the ARCHES trial and related ENZAMET trial, which demonstrated showed the use of enzalutamide improved survival and reduced disease progression in men with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Armstrong compares enzalutamide to first-generation androgen receptor inhibitors such as flutamide and bicalutamide, discusses the strong results supporting enzalutamide in both trials, and the implications for future mHSPC treatment using androgen deprivation.
ABOUT THE AUTHOR
Andrew J. Armstrong, MD, MSc, FACP, is a tenured Professor of Medicine, Urology, and Pharmacology and Cancer Biology at Duke University in Durham, North Carolina. Dr. Armstrong is a member of the Duke Cancer Institute and has developed a number of experimental agents in prostate and renal cell cancer, including AR inhibitors, immunotherapies, mTOR/PI3K inhibitors, and anti-angiogenic agents. He is an internationally-recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer.
